X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Pyrilutamide
Therapeutic Area: Dermatology Product Name: KX-826
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 16, 2021
Details:
The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of Pyrilutamide in patients with mild to moderate acne vulgaris.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GT20029
Therapeutic Area: Dermatology Product Name: GT20029
Highest Development Status: IND Enabling Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2021
Details:
GT20029 is a topical androgen receptor degrader developed by using Kintor's in-house PROTAC platform. PROTAC is a small molecule composed of a recruiting element for a protein of interest; an E3 ubiquitin ligase recruiting element; and a linker bounding (i) and (ii).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
